Q-omics provides the consensus-scored ATOH1 profile across patient tissues and cancer cell-line models. ATOH1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ATOH1 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, ATOH1 RNA expression shows 10,086 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, and TGCT as cancer lineages where ATOH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATOH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATOH1 survival associations across molecular data types. ATOH1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATOH1 RNA expression–survival associations across cancer types. High ATOH1 expression shows unfavorable associations in HNSC, KIRC, KICH and ESCA, but favorable associations in COAD and PAAD. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ATOH1 RNA expression.
This table summarizes ATOH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ATOH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATOH1 shows lower tumor expression in COAD and THCA and higher tumor expression in PRAD, UCEC, LUSC and KIRP. The COAD box plot shows higher ATOH1 RNA expression in normal versus tumor tissue (log2 FC = −2.594, t-test p < 0.001).
This table shows molecular features associated with ATOH1 in patient tissues and cancer cell lines. In patient samples, ATOH1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ATOH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
